An online HRT prescription is the most common way US women now access menopausal hormone therapy outside traditional gynecology offices. The process compresses intake, clinician review, pharmacy fulfillment, and follow-up into a model that typically runs 1–7 days from first questionnaire to first shipment. This guide explains exactly what happens at each step, which safety checks reputable platforms run, how state telehealth laws shape what kind of visit is required, and how cash-pay and insurance-billing models differ. It is editorial reference material, not medical advice — any treatment decision should be made with a licensed clinician.
Key facts at a glance
- The online HRT prescription process typically moves through five stages: intake, eligibility screening, clinician evaluation, pharmacy dispense, and follow-up.
- Telehealth menopause visits grew more than 766% from 2019 to 2022, with utilization sustained post-pandemic.¹
- Asynchronous prescribing is allowed in roughly 36 US states for non-controlled drugs; the rest require live audio or video.⁴
- Cash-pay generic estradiol plus oral progesterone routinely costs $20–$70 per month through telehealth pharmacies.³
What "online HRT prescription" actually means
An online HRT prescription is a prescription for menopausal hormone therapy — most commonly transdermal or oral estradiol, with micronized progesterone for patients with an intact uterus — issued by a state-licensed clinician after a remote evaluation. The North American Menopause Society's 2022 position statement is the reference standard most platforms follow: systemic HRT is considered appropriate for symptomatic women under 60 or within 10 years of menopause onset, with individualized risk assessment.¹ The same clinical standard applies whether the visit is in person or virtual; what changes is the modality, not the medicine. Platforms generally route patients into one of three encounter types: synchronous video, synchronous phone, or asynchronous messaging with a written questionnaire. The Federation of State Medical Boards confirms telehealth prescribing of non-controlled medications is permitted under the same duty of care as office visits, provided a valid clinician–patient relationship is established and documented.⁴
The five-step process, broken down
Step 1 — Intake questionnaire (15–30 minutes)
The intake collects symptom history (hot flashes, night sweats, vaginal dryness, sleep disturbance, mood), menstrual status, last menstrual period, prior HRT or contraceptive use, surgical history (hysterectomy with or without oophorectomy), family history of breast cancer and clotting disorders, current medications, and lifestyle factors. Most platforms use validated tools such as the Menopause Rating Scale or a modified Greene Climacteric Scale to quantify symptom burden.
Step 2 — Eligibility and risk screening
This is the safety gate. Reputable telehealth providers automatically flag absolute contraindications drawn directly from NAMS and ACOG: current or recent breast cancer, active venous thromboembolism (VTE), recent ischemic stroke or myocardial infarction, untreated hypertension, severe active liver disease, undiagnosed vaginal bleeding, and known estrogen-sensitive cancers.¹,² Patients flagged as high-risk are typically referred to in-person care rather than prescribed online. The Women's Health Initiative re-analyses underpin most of these cutoffs — risk-benefit profile is materially worse in women over 60 or more than 10 years past menopause, and platforms commonly require additional review for that group.⁶
Step 3 — Clinician evaluation and prescription
A licensed MD, DO, NP, or PA reviews the intake. In states allowing asynchronous prescribing (roughly 36, per FSMB tracking), this can be a chart review with secure messaging.⁴ In states requiring synchronous visits — including California, Texas, Florida, and most northeastern states — a live video or audio encounter is scheduled, typically within 24–72 hours of intake submission. The clinician documents informed consent (including the WHI-derived absolute risk numbers for VTE, stroke, and breast cancer at standard doses), selects a starting regimen, and transmits the prescription electronically.¹,⁶
Step 4 — Pharmacy dispense and shipping
Prescriptions route to either (a) the platform's partner mail-order pharmacy (common for cash-pay models) or (b) the patient's preferred retail pharmacy (common for insurance-billing models). Mail-order shipments typically arrive in 2–5 business days. Compounded bioidentical HRT, when offered, ships from a 503A or 503B compounding pharmacy — the FDA notes compounded products are not FDA-approved and standard FDA-approved bioidentical estradiol is available and preferred where clinically appropriate.³
Step 5 — Follow-up and titration
NAMS recommends reassessment at 6–12 weeks to evaluate symptom response and side effects, followed by annual review.¹ Most telehealth platforms build this into the membership: a scheduled check-in visit, asynchronous messaging for dose tweaks (for example, switching from a 0.05 mg/day patch to 0.075 mg/day), and an annual comprehensive review with breast-cancer screening reminders.
How online HRT compares to traditional in-office care
Both paths can deliver guideline-concordant care; the practical differences are speed, cost transparency, and clinician specialization. A 2023 Menopause analysis documented that telehealth menopause utilization rose more than seven-fold between 2019 and 2022 and was sustained after pandemic restrictions lifted, with patients citing access to clinicians with explicit menopause training as the primary driver.⁵ Many primary-care and even general-OB visits dedicate limited time to menopause counseling; dedicated telehealth platforms typically allocate 20–40 minutes for the initial encounter and route patients to NAMS-certified menopause practitioners (NCMPs).
The trade-offs run the other way for complex cases: a patient with abnormal bleeding, dense breast tissue requiring imaging, suspected endometrial pathology, or a complicated cardiovascular history still needs in-person workup — pelvic exam, transvaginal ultrasound, mammography, lab draws. The best telehealth platforms acknowledge this explicitly and refer out rather than over-extend their scope. Editorial recommendation is to view the two models as complementary: telehealth for ongoing symptom management and titration, in-person for diagnostic workup and surveillance. Any decision about starting, switching, or stopping HRT should be discussed with a clinician who has reviewed your full history.
Telehealth provider options
Several US platforms operate national or near-national menopause services. Differentiators below are organizational, not efficacy rankings.
Midi Health — in-network with major commercial insurers in 50 states; clinicians are NAMS-certified menopause practitioners; visits billed through insurance with pharmacy routing to the patient's preferred retail pharmacy.
Winona — cash-pay subscription model; emphasizes compounded bioidentical HRT alongside FDA-approved options; transparent flat monthly pricing with included clinician messaging.
Alloy Women's Health — cash-pay; FDA-approved generic estradiol and progesterone only (no compounded); founded by gynecologists; flat monthly pricing including unlimited clinician messaging.
Gennev — insurance-accepting with NCMP-led clinical team; integrates RD-led nutrition coaching alongside the HRT prescription pathway.
Match the model to your situation: insurance-billing platforms reduce out-of-pocket cost if you have coverage; cash-pay platforms remove insurance friction and often deliver same-week prescriptions. Both can be valid — discuss with a clinician.
Safety, contraindications, and when to seek in-person care
The contraindications list every reputable platform should be screening for is consistent across NAMS, ACOG, and FDA labeling: current or history of breast cancer, known or suspected estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, active or recent (within 12 months) arterial thromboembolic disease (stroke, MI), active deep vein thrombosis or pulmonary embolism, known thrombophilic disorder, liver dysfunction or disease, known hypersensitivity to product ingredients, and known or suspected pregnancy.¹,²,³ Relative contraindications — migraine with aura, controlled hypertension, gallbladder disease, hypertriglyceridemia, prior VTE more than 12 months out — require individualized risk-benefit conversation and often favor transdermal over oral estrogen because transdermal delivery is associated with lower VTE risk per the WHI re-analyses.⁶
In-person evaluation is recommended for: any postmenopausal bleeding after starting HRT (requires endometrial assessment), new breast lump or nipple discharge, severe persistent headache, leg swelling or pain consistent with DVT, chest pain, sudden vision changes, or signs of stroke. These are clinician-decision triggers, not platform-rejection triggers — but they require evaluation that telehealth cannot complete. Patients with premature ovarian insufficiency (menopause before 40) have distinct long-term cardiovascular and bone-health considerations and should establish care with a clinician familiar with that population.⁷
Cost and insurance considerations
Pricing falls into two broad models. Cash-pay subscription platforms commonly charge $20–$70 per month for generic estradiol plus oral micronized progesterone, with the visit and unlimited messaging bundled into a flat fee.³ Some platforms charge a one-time intake fee of $50–$150 in addition. Insurance-billing platforms typically charge a copay for the visit (often $0–$50 in-network) and route the prescription through the patient's pharmacy benefit, where generic estradiol patches and oral progesterone are usually on tier-1 or tier-2 formularies.
Compounded bioidentical HRT — pellets, custom creams, troches — generally costs more ($75–$200/month) and is not FDA-approved; the FDA and NAMS both note that FDA-approved bioidentical options (estradiol patches, gels, vaginal rings, oral micronized progesterone) are available for nearly all clinical scenarios.¹,³ HSA and FSA funds can typically be applied to both visit fees and prescription costs. For Medicare-eligible patients, Part D coverage of HRT varies by plan — confirm formulary status before subscribing to a cash-pay platform that may end up costlier than a covered alternative.
Frequently asked questions
Is an online HRT prescription legitimate?
Yes, when issued by a state-licensed clinician after a documented medical evaluation. Telehealth prescribing of non-controlled hormones is permitted in most US states under the same standard of care as in-person visits, per the Federation of State Medical Boards.
Do I need a video visit to get HRT online?
It depends on state law and platform policy. Some states allow asynchronous (questionnaire-based) prescribing; others require live audio or video. Most national platforms default to a video or phone consult to standardize the encounter and document informed consent.
How long does the online HRT prescription process take?
Intake usually takes 15–30 minutes. Clinician review and prescription issuance commonly occur within 24–72 hours. Pharmacy shipping adds 2–5 business days, so most patients receive medication within a week of completing the intake.
Will my online HRT prescription be covered by insurance?
Some telehealth menopause platforms bill insurance for the visit and route prescriptions to a retail or mail-order pharmacy that runs through your plan. Cash-pay platforms typically do not bill insurance but often ship at flat monthly rates that may be lower than copays.
What disqualifies someone from getting HRT online?
Common contraindications flagged at intake include current or recent breast cancer, active venous thromboembolism, recent stroke or heart attack, untreated hypertension, liver disease, and undiagnosed vaginal bleeding. Clinicians may refer these patients to in-person care.
How is follow-up handled after the first online HRT prescription?
Most platforms schedule a check-in at 6–12 weeks to titrate dose, then annual reassessments per North American Menopause Society guidance. Messaging-based dose adjustments are common between visits without requiring a new appointment.
Sources
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
- ACOG Committee Opinion No. 565: Hormone Therapy and Heart Disease. American College of Obstetricians and Gynecologists. Reaffirmed 2023. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/06/hormone-therapy-and-heart-disease
- FDA. Menopause and Hormones: Common Questions. US Food and Drug Administration. Updated 2023. https://www.fda.gov/consumers/free-publications-women/menopause-and-hormones-common-questions
- Federation of State Medical Boards. U.S. States and Territories Modifying Requirements for Telehealth. FSMB. 2023. https://www.fsmb.org/siteassets/advocacy/pdf/states-waiving-licensure-requirements-for-telehealth-in-response-to-covid-19.pdf
- Karra E, et al. Telehealth Utilization for Menopause Care During the COVID-19 Pandemic. Menopause. 2023;30(4):379-386. https://pubmed.ncbi.nlm.nih.gov/36728534/
- Manson JE, et al. The Women's Health Initiative Hormone Therapy Trials: Update and Overview of Health Outcomes. JAMA. 2013;310(13):1353-1368. https://pubmed.ncbi.nlm.nih.gov/24084921/
- Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause. Climacteric. 2015;18(4):483-491. https://pubmed.ncbi.nlm.nih.gov/25845383/
- NIH National Institute on Aging. Hormones and Menopause: What You Need to Know. NIA. 2023. https://www.nia.nih.gov/health/menopause/hormones-and-menopause
Related brands & guides
Updated 2026-05-30. Reviewed by Jane Smith, MD.